In recent times there is increased use of molecular diagnostics due to increasing application in blood screening, genetic disorders and cancer. Increasing prevalence of chronic and infectious diseases such as HIV and hepatitis, rising awareness and acceptance of personalized medicine and companion diagnostics are also fueling growth in the global molecular diagnostics market. However, changing reimbursement regulations and delayed approval of many new molecular diagnostic tests are some of the factors inhibiting the growth for global molecular diagnostics market.
North America dominates the global market of molecular diagnostics due to increasing incidence of infectious diseases and lifestyle associated diseases. In addition, innovations in molecular diagnostics for treating cancer, government support for research and development, and high patient awareness levels are driving the growth of molecular diagnostic market in North America. Asia is expected to show high growth rates in the next five years in molecular diagnostics market. Some of the factors driving growth of molecular diagnostics in emerging markets are increasing demand of genetic tests, advancement in healthcare infrastructure and large patient pool in countries such as India and China.
Inquire for a Sample Copy of Report – https://www.persistencemarketresearch.com/samples/2784
Growing demand for genetic tests is an opportunity for global molecular diagnostics market. However, strict regulatory framework and lack of skilled labor are some of the major challenges for global molecular diagnostics market. Some of the major companies operating in global molecular diagnostics market are Novartis AG, Roche Diagnostics, QIAGEN, Siemens Healthcare, Abbott Laboratories, Inc., Gen-Probe, Inc. (Hologic Inc.), Cepheid, Inc., Beckman Coulter, Inc., Becton, Dickinson & Company, Myriad Genetics, Inc., and bioMerieux.